Article
In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition.
Journal of experimental & clinical cancer research : CR - 12 Jul 2025
Heidrich Isabel, Rautmann Charlotte, Ly Cedric, Khatri Robin, Kött Julian, Geidel Glenn, Rünger Alessandra, Andreas Antje, Hansen-Abeck Inga, Abeck Finn, Menz Anne, Bonn Stefan, Schneider Stefan W, Smit Daniel J, Gebhardt Christoffer, Pantel Klaus
Abstract excerpt
INTRODUCTION: Circulating tumor DNA (ctDNA) holds promise for guiding immune checkpoint inhibitor (ICI) therapy and stratifying responders from non-responders. While tumor-informed ctDNA detection approaches are sensitive and mutation-inclusive, they require tumor tissue, which limits applicability in real-world settings. Conversely, tumor-agnostic methods often have limited genomic coverage. In this study, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.